Metabolomics: Analytical Insights into Disease Mechanisms and Biomarker Discovery
Main Article Content
Abstract
Metabolomics is an interdisciplinary field that combines advanced analytical chemistry techniques with biology to comprehensively identify and quantify metabolites present in cells, tissues, and biofluids. It serves as a powerful tool for understanding the biochemical underpinnings of various physiological and pathological processes. By capturing the dynamic changes in the metabolome, this approach offers a snapshot of the functional state of biological systems. Over the past decade, metabolomics has been extensively employed in the search for novel biomarkers that are clinically relevant, aiding in early diagnosis, prognosis, and therapeutic monitoring. Recent advancements in technologies such as mass spectrometry and nuclear magnetic resonance spectroscopy have significantly enhanced the sensitivity, accuracy, and throughput of metabolomic studies. These developments have contributed to a deeper understanding of the roles metabolites play in human pathophysiology. This review presents an updated overview of the latest techniques and analytical strategies used in metabolomics research. It also highlights the application of metabolomics in exploring metabolic alterations associated with neurological conditions, cancer, and lifestyle diseases including diabetes and coronary heart disease. The broad impact and growing utility of metabolomics hold great promise for driving innovation in disease prevention, personalized treatment strategies, and improved healthcare outcomes.
Keywords:
Metabolomics, Gas Chromatography Mass Spectrometry, Liquid Chromatography Mass Spectrometry, Nuclear Magnetic Resonance, Biomarkers
Article Details
How to Cite
TOMAR, Manendra Singh et al.
Metabolomics: Analytical Insights into Disease Mechanisms and Biomarker Discovery.
Medical Research Archives, [S.l.], v. 13, n. 6, june 2025.
ISSN 2375-1924.
Available at: <https://esmed.org/MRA/mra/article/view/6549>. Date accessed: 17 july 2025.
doi: https://doi.org/10.18103/mra.v13i6.6549.
Section
Research Articles
The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.
References
1. German JB, Hammock BD, Watkins SM. Metabolomics: building on a century of biochemistry to guide human health. Metabolomics : Official journal of the Metabolomic Society. 2005;1(1):3-9.
2. Dar MA, Arafah A, Bhat KA, et al. Multiomics technologies: role in disease biomarker discoveries and therapeutics. Briefings in functional genomics. 2023;22(2):76-96.
3. Aderemi AV, Ayeleso AO, Oyedapo OO, Mukwevho E. Metabolomics: A Scoping Review of Its Role as a Tool for Disease Biomarker Discovery in Selected Non-Communicable Diseases. Metabolites. 2021;11(7).
4. Johnson CH, Ivanisevic J, Siuzdak G. Metabolomics: beyond biomarkers and towards mechanisms. Nature reviews Molecular cell biology. 2016;17(7):451-459.
5. Johnson CH, Patterson AD, Idle JR, Gonzalez FJ. Xenobiotic metabolomics: major impact on the metabolome. Annual review of pharmacology and toxicology. 2012;52:37-56.
6. Kim HM, Kang JS. Metabolomic Studies for the Evaluation of Toxicity Induced by Environmental Toxicants on Model Organisms. Metabolites. 2021;11(8).
7. Whitfield PD, German AJ, Noble PJ. Metabolomics: an emerging post-genomic tool for nutrition. The British journal of nutrition. 2004;92(4):549-555.
8. Bino RJ, Hall RD, Fiehn O, et al. Potential of metabolomics as a functional genomics tool. Trends in plant science. 2004;9(9):418-425.
9. Wishart DS. Emerging applications of metabolomics in drug discovery and precision medicine. Nature reviews Drug discovery. 2016;15(7):473-484.
10. Rinschen MM, Ivanisevic J, Giera M, Siuzdak G. Identification of bioactive metabolites using activity metabolomics. Nature reviews Molecular cell biology. 2019;20(6):353-367.
11. Liu X, Locasale JW. Metabolomics: A Primer. Trends in biochemical sciences. 2017;42(4):274-284.
12. Zamboni N, Saghatelian A, Patti GJ. Defining the metabolome: size, flux, and regulation. Molecular cell. 2015;58(4):699-706.
13. Gika HG, Zisi C, Theodoridis G, Wilson ID. Protocol for quality control in metabolic profiling of biological fluids by U(H)PLC-MS. Journal of chromatography B, Analytical technologies in the biomedical and life sciences. 2016;1008:15-25.
14. Ashrafian H, Sounderajah V, Glen R, et al. Metabolomics: The Stethoscope for the Twenty-First Century. Medical principles and practice : international journal of the Kuwait University, Health Science Centre. 2021;30(4):301-310.
15. Pang H, Jia W, Hu Z. Emerging Applications of Metabolomics in Clinical Pharmacology. Clinical pharmacology and therapeutics. 2019;106(3):544-556.
16. Gonzalez-Covarrubias V, Martínez-Martínez E, Del Bosque-Plata L. The Potential of Metabolomics in Biomedical Applications. Metabolites. 2022;12(2).
17. Beger RD. A review of applications of metabolomics in cancer. Metabolites. 2013;3(3):552-574.
18. Bourgognon JM, Steinert JR. The metabolome identity: basis for discovery of biomarkers in neurodegeneration. Neural regeneration research. 2019;14(3):387-390.
19. Wang JH, Byun J, Pennathur S. Analytical approaches to metabolomics and applications to systems biology. Seminars in nephrology. 2010;30(5):500-511.
20. Zhang XW, Li QH, Xu ZD, Dou JJ. Mass spectrometry-based metabolomics in health and medical science: a systematic review. RSC advances. 2020;10(6):3092-3104.
21. Dettmer K, Aronov PA, Hammock BD. Mass spectrometry-based metabolomics. Mass spectrometry reviews. 2007;26(1):51-78.
22. Fiehn O. Metabolomics by Gas Chromatography-Mass Spectrometry: Combined Targeted and Untargeted Profiling. Current protocols in molecular biology. 2016;114:30.34.31-30.34.32.
23. Kiseleva O, Kurbatov I, Ilgisonis E, Poverennaya E. Defining Blood Plasma and Serum Metabolome by GC-MS. Metabolites. 2021;12(1).
24. Mostafa A, Edwards M, Górecki T. Optimization aspects of comprehensive two-dimensional gas chromatography. Journal of chromatography A. 2012;1255:38-55.
25. Allen DR, McWhinney BC. Quadrupole Time-of-Flight Mass Spectrometry: A Paradigm Shift in Toxicology Screening Applications. The Clinical biochemist Reviews. 2019;40(3):135-146.
26. Zhou B, Xiao JF, Tuli L, Ressom HW. LC-MS-based metabolomics. Molecular bioSystems. 2012;8(2):470-481.
27. Singh RR, Chao A, Phillips KA, et al. Expanded coverage of non-targeted LC-HRMS using atmospheric pressure chemical ionization: a case study with ENTACT mixtures. Analytical and bioanalytical chemistry. 2020;412(20):4931-4939.
28. Xiao JF, Zhou B, Ressom HW. Metabolite identification and quantitation in LC-MS/MS-based metabolomics. Trends in analytical chemistry : TRAC. 2012;32:1-14.
29. Liu X, Tian X, Qinghong S, et al. Characterization of LC-MS based urine metabolomics in healthy children and adults. PeerJ. 2022;10:e13545.
30. Adamski J. Genome-wide association studies with metabolomics. Genome medicine. 2012;4(4):34.
31. Nagana Gowda GA, Raftery D. NMR-Based Metabolomics. Advances in experimental medicine and biology. 2021;1280:19-37.
32. Nerli S, McShan AC, Sgourakis NG. Chemical shift-based methods in NMR structure determination. Progress in nuclear magnetic resonance spectroscopy. 2018;106-107:1-25.
33. Belhaj MR, Lawler NG, Hoffman NJ. Metabolomics and Lipidomics: Expanding the Molecular Landscape of Exercise Biology. Metabolites. 2021;11(3).
34. Crook AA, Powers R. Quantitative NMR-Based Biomedical Metabolomics: Current Status and Applications. Molecules (Basel, Switzerland). 2020;25(21).
35. Gowda GA, Zhang S, Gu H, Asiago V, Shanaiah N, Raftery D. Metabolomics-based methods for early disease diagnostics. Expert review of molecular diagnostics. 2008;8(5):617-633.
36. Kumar D, Gupta A, Nath K. NMR-based metabolomics of prostate cancer: a protagonist in clinical diagnostics. Expert review of molecular diagnostics. 2016;16(6):651-661.
37. Xi B, Gu H, Baniasadi H, Raftery D. Statistical analysis and modeling of mass spectrometry-based metabolomics data. Methods in molecular biology (Clifton, NJ). 2014;1198:333-353.
38. Saccenti E, Hoefsloot HCJ, Smilde AK, Westerhuis JA, Hendriks MMWB. Reflections on univariate and multivariate analysis of metabolomics data. Metabolomics : Official journal of the Metabolomic Society. 2014;10(3):361-374.
39. Pang Z, Chong J, Zhou G, et al. MetaboAnalyst 5.0: narrowing the gap between raw spectra and functional insights. Nucleic acids research. 2021;49(W1):W388-w396.
40. Xia J, Psychogios N, Young N, Wishart DS. MetaboAnalyst: a web server for metabolomic data analysis and interpretation. Nucleic acids research. 2009;37(Web Server issue):W652-660.
41. Gowda GA, Djukovic D. Overview of mass spectrometry-based metabolomics: opportunities and challenges. Methods in molecular biology (Clifton, NJ). 2014;1198:3-12.
42. Costa C, Maraschin M, Rocha M. An R package for the integrated analysis of metabolomics and spectral data. Computer methods and programs in biomedicine. 2016;129:117-124.
43. Sumner LW, Amberg A, Barrett D, et al. Proposed minimum reporting standards for chemical analysis Chemical Analysis Working Group (CAWG) Metabolomics Standards Initiative (MSI). Metabolomics : Official journal of the Metabolomic Society. 2007;3(3):211-221.
44. Couch RD, Dailey A, Zaidi F, et al. Alcohol Induced Alterations to the Human Fecal VOC Metabolome. PLOS ONE. 2015;10(3):e0119362.
45. Mahmud I, Thapaliya M, Boroujerdi A, Chowdhury K. NMR-based metabolomics study of the biochemical relationship between sugarcane callus tissues and their respective nutrient culture media. Analytical and bioanalytical chemistry. 2014;406(24):5997-6005.
46. Kwak S. Are Only p-Values Less Than 0.05 Significant? A p-Value Greater Than 0.05 Is Also Significant! Journal of lipid and atherosclerosis. 2023;12(2):89-95.
47. Tzoulaki I, Ebbels TM, Valdes A, Elliott P, Ioannidis JP. Design and analysis of metabolomics studies in epidemiologic research: a primer on -omic technologies. American journal of epidemiology. 2014;180(2):129-139.
48. Worley B, Powers R. Multivariate Analysis in Metabolomics. Current Metabolomics. 2013;1(1):92-107.
49. Jolliffe IT, Cadima J. Principal component analysis: a review and recent developments. Philosophical transactions Series A, Mathematical, physical, and engineering sciences. 2016;374(2065):20150202.
50. Worley B, Powers R. PCA as a practical indicator of OPLS-DA model reliability. Current Metabolomics. 2016;4(2):97-103.
51. Debik J, Sangermani M, Wang F, Madssen TS, Giskeødegård GF. Multivariate analysis of NMR-based metabolomic data. NMR in biomedicine. 2022;35(2):e4638.
52. Moholdt T, Parr EB, Devlin BL, Debik J, Giskeødegård G, Hawley JA. The effect of morning vs evening exercise training on glycaemic control and serum metabolites in overweight/obese men: a randomised trial. Diabetologia. 2021;64(9):2061-2076.
53. Chang W-C. On Using Principal Components Before Separating a Mixture of Two Multivariate Normal Distributions. Journal of the Royal Statistical Society Series C (Applied Statistics). 1983;32(3):267-275.
54. Nyamundanda G, Brennan L, Gormley IC. Probabilistic principal component analysis for metabolomic data. BMC bioinformatics. 2010;11:571.
55. Gromski PS, Muhamadali H, Ellis DI, et al. A tutorial review: Metabolomics and partial least squares-discriminant analysis--a marriage of convenience or a shotgun wedding. Analytica chimica acta. 2015;879:10-23.
56. Worley B, Halouska S, Powers R. Utilities for quantifying separation in PCA/PLS-DA scores plots. Analytical biochemistry. 2013;433(2):102-104.
57. Lee LC, Liong CY, Jemain AA. Partial least squares-discriminant analysis (PLS-DA) for classification of high-dimensional (HD) data: a review of contemporary practice strategies and knowledge gaps. The Analyst. 2018;143(15):3526-3539.
58. Ruiz-Perez D, Guan H, Madhivanan P, Mathee K, Narasimhan G. So you think you can PLS-DA? BMC bioinformatics. 2020;21(Suppl 1):2.
59. Tan Y, Shi L, Tong W, Hwang GT, Wang C. Multi-class tumor classification by discriminant partial least squares using microarray gene expression data and assessment of classification models. Computational biology and chemistry. 2004;28(3):235-244.
60. Botella C, Ferré J, Boqué R. Classification from microarray data using probabilistic discriminant partial least squares with reject option. Talanta. 2009;80(1):321-328.
61. Ruiz-Perez D, Guan H, Madhivanan P, Mathee K, Narasimhan G. So you think you can PLS-DA? BMC bioinformatics. 2020;21(1):2.
62. KA LC, Boitard S, Besse P. Sparse PLS discriminant analysis: biologically relevant feature selection and graphical displays for multiclass problems. BMC bioinformatics. 2011;12:253.
63. Bastien P, Bertrand F, Meyer N, Maumy-Bertrand M. Deviance residuals-based sparse PLS and sparse kernel PLS regression for censored data. Bioinformatics (Oxford, England). 2015;31(3):397-404.
64. Chung D, Keles S. Sparse partial least squares classification for high dimensional data. Statistical applications in genetics and molecular biology. 2010;9(1):Article17.
65. Lee D, Lee Y, Pawitan Y, Lee W. Sparse partial least-squares regression for high-throughput survival data analysis. Statistics in medicine. 2013;32(30):5340-5352.
66. Vajargah KF, Sadeghi-Bazargani H, Mehdizadeh-Esfanjani R, Savadi-Oskouei D, Farhoudi M. OPLS statistical model versus linear regression to assess sonographic predictors of stroke prognosis. Neuropsychiatric disease and treatment. 2012;8:387-392.
67. Shah SH, Kraus WE, Newgard CB. Metabolomic profiling for the identification of novel biomarkers and mechanisms related to common cardiovascular diseases: form and function. Circulation. 2012;126(9):1110-1120.
68. Collino S, Martin FP, Rezzi S. Clinical metabolomics paves the way towards future healthcare strategies. British journal of clinical pharmacology. 2013;75(3):619-629.
69. Buergel T, Steinfeldt J, Ruyoga G, et al. Metabolomic profiles predict individual multidisease outcomes. Nature medicine. 2022;28(11):2309-2320.
70. Martínez-Reyes I, Chandel NS. Cancer metabolism: looking forward. Nature reviews Cancer. 2021;21(10):669-680.
71. Schmidt DR, Patel R, Kirsch DG, Lewis CA, Vander Heiden MG, Locasale JW. Metabolomics in cancer research and emerging applications in clinical oncology. CA: a cancer journal for clinicians. 2021;71(4):333-358.
72. Han J, Li Q, Chen Y, Yang Y. Recent Metabolomics Analysis in Tumor Metabolism Reprogramming. Frontiers in molecular biosciences. 2021;8:763902.
73. Nascentes Melo LM, Lesner NP, Sabatier M, Ubellacker JM, Tasdogan A. Emerging metabolomic tools to study cancer metastasis. Trends in cancer. 2022;8(12):988-1001.
74. An R, Yu H, Wang Y, et al. Integrative analysis of plasma metabolomics and proteomics reveals the metabolic landscape of breast cancer. Cancer & metabolism. 2022;10(1):13.
75. Hassan MA, Al-Sakkaf K, Shait Mohammed MR, et al. Integration of Transcriptome and Metabolome Provides Unique Insights to Pathways Associated With Obese Breast Cancer Patients. Frontiers in oncology. 2020;10:804.
76. Resurreccion EP, Fong KW. The Integration of Metabolomics with Other Omics: Insights into Understanding Prostate Cancer. Metabolites. 2022;12(6).
77. Liberti MV, Locasale JW. The Warburg Effect: How Does it Benefit Cancer Cells? Trends in biochemical sciences. 2016;41(3):211-218.
78. DeBerardinis RJ, Mancuso A, Daikhin E, et al. Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proceedings of the National Academy of Sciences of the United States of America. 2007;104(49):19345-19350.
79. Lafita-Navarro MC, Perez-Castro L, Zacharias LG, Barnes S, DeBerardinis RJ, Conacci-Sorrell M. The transcription factors aryl hydrocarbon receptor and MYC cooperate in the regulation of cellular metabolism. The Journal of biological chemistry. 2020;295(35):12398-12407.
80. Sica V, Bravo-San Pedro JM, Stoll G, Kroemer G. Oxidative phosphorylation as a potential therapeutic target for cancer therapy. International journal of cancer. 2020;146(1):10-17.
81. Ashton TM, McKenna WG, Kunz-Schughart LA, Higgins GS. Oxidative Phosphorylation as an Emerging Target in Cancer Therapy. Clinical cancer research : an official journal of the American Association for Cancer Research. 2018;24(11):2482-2490.
82. Giddings EL, Champagne DP, Wu MH, et al. Mitochondrial ATP fuels ABC transporter-mediated drug efflux in cancer chemoresistance. Nature communications. 2021;12(1):2804.
83. Caro P, Kishan AU, Norberg E, et al. Metabolic signatures uncover distinct targets in molecular subsets of diffuse large B cell lymphoma. Cancer cell. 2012;22(4):547-560.
84. Patra KC, Hay N. The pentose phosphate pathway and cancer. Trends in biochemical sciences. 2014;39(8):347-354.
85. Li L, Zheng X, Zhou Q, et al. Metabolomics-Based Discovery of Molecular Signatures for Triple Negative Breast Cancer in Asian Female Population. Scientific reports. 2020;10(1):370.
86. Lima AR, Pinto J, Bastos ML, Carvalho M, Guedes de Pinho P. NMR-based metabolomics studies of human prostate cancer tissue. Metabolomics : Official journal of the Metabolomic Society. 2018;14(7):88.
87. Yu L, Lai Q, Feng Q, Li Y, Feng J, Xu B. Serum Metabolic Profiling Analysis of Chronic Gastritis and Gastric Cancer by Untargeted Metabolomics. Frontiers in oncology. 2021;11:636917.
88. Tripathi P, Somashekar BS, Ponnusamy M, et al. HR-MAS NMR tissue metabolomic signatures cross-validated by mass spectrometry distinguish bladder cancer from benign disease. Journal of proteome research. 2013;12(7):3519-3528.
89. Zhou H, Li L, Zhao H, et al. A Large-Scale, Multi-Center Urine Biomarkers Identification of Coronary Heart Disease in TCM Syndrome Differentiation. Journal of proteome research. 2019;18(5):1994-2003.
90. Ullah E, El-Menyar A, Kunji K, et al. METABOLOMICS REVEALS PERTURBATIONS IN ARGININE-NO METABOLISM, PURINE BIOSYNTHESIS AND CELLULAR ENERGY CHARGE IN PATIENTS WITH CORONARY HEART DISEASE. Journal of the American College of Cardiology. 2021;77:22.
91. Kordalewska M, Markuszewski MJ. Metabolomics in cardiovascular diseases. Journal of pharmaceutical and biomedical analysis. 2015;113:121-136.
92. Senn T, Hazen SL, Tang WH. Translating metabolomics to cardiovascular biomarkers. Progress in cardiovascular diseases. 2012;55(1):70-76.
93. Li B, Gao G, Zhang W, et al. Metabolomics analysis reveals an effect of homocysteine on arachidonic acid and linoleic acid metabolism pathway. Molecular medicine reports. 2018;17(5):6261-6268.
94. Stratmann B, Richter K, Wang R, et al. Metabolomic Signature of Coronary Artery Disease in Type 2 Diabetes Mellitus. International journal of endocrinology. 2017;2017:7938216.
95. Rangel-Huerta OD, Pastor-Villaescusa B, Gil A. Are we close to defining a metabolomic signature of human obesity? A systematic review of metabolomics studies. Metabolomics : Official journal of the Metabolomic Society. 2019;15(6):93.
96. Taghizadeh H, Emamgholipour S, Hosseinkhani S, et al. The association between acylcarnitine and amino acids profile and metabolic syndrome and its components in Iranian adults: Data from STEPs 2016. Frontiers in endocrinology. 2023;14:1058952.
97. Gupta S, Sharma U. Metabolomics of neurological disorders in India. Analytical Science Advances. 2021;2(11-12):594-610.
98. Quintero ME, Pontes JGM, Tasic L. Metabolomics in degenerative brain diseases. Brain research. 2021;1773:147704.
99. Roche S, Gabelle A, Lehmann S. Clinical proteomics of the cerebrospinal fluid: Towards the discovery of new biomarkers. Proteomics Clinical applications. 2008;2(3):428-436.
100. Huo Z, Yu L, Yang J, Zhu Y, Bennett DA, Zhao J. Brain and blood metabolome for Alzheimer's dementia: findings from a targeted metabolomics analysis. Neurobiology of aging. 2020;86:123-133.
101. Haass C, Kaether C, Thinakaran G, Sisodia S. Trafficking and proteolytic processing of APP. Cold Spring Harbor perspectives in medicine. 2012;2(5):a006270.
102. Liu CC, Liu CC, Kanekiyo T, Xu H, Bu G. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nature reviews Neurology. 2013;9(2):106-118.
103. Burke SL, Maramaldi P, Cadet T, Kukull W. Associations between depression, sleep disturbance, and apolipoprotein E in the development of Alzheimer's disease: dementia. International psychogeriatrics. 2016;28(9):1409-1424.
104. Klosinski LP, Yao J, Yin F, et al. White Matter Lipids as a Ketogenic Fuel Supply in Aging Female Brain: Implications for Alzheimer's Disease. EBioMedicine. 2015;2(12):1888-1904.
105. Wilkins JM, Trushina E. Application of Metabolomics in Alzheimer's Disease. Frontiers in neurology. 2017;8:719.
106. Horgusluoglu E, Neff R, Song WM, et al. Integrative metabolomics-genomics approach reveals key metabolic pathways and regulators of Alzheimer's disease. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2022;18(6):1260-1278.
107. Liang Q, Liu H, Zhang T, Jiang Y, Xing H, Zhang A-h. Metabolomics-based screening of salivary biomarkers for early diagnosis of Alzheimer's disease. RSC advances. 2015;5(116):96074-96079.
108. Batra R, Arnold M, Wörheide MA, et al. The landscape of metabolic brain alterations in Alzheimer's disease. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2022.
109. Varma VR, Oommen AM, Varma S, et al. Brain and blood metabolite signatures of pathology and progression in Alzheimer disease: A targeted metabolomics study. PLoS medicine. 2018;15(1):e1002482.
110. Fiehn O. Metabolomics--the link between genotypes and phenotypes. Plant molecular biology. 2002;48(1-2):155-171.
111. Aarsland D, Batzu L, Halliday GM, et al. Parkinson disease-associated cognitive impairment. Nature reviews Disease primers. 2021;7(1):47.
112. Shao Y, Le W. Recent advances and perspectives of metabolomics-based investigations in Parkinson's disease. Molecular neurodegeneration. 2019;14(1):3.
113. LeWitt PA, Li J, Lu M, Guo L, Auinger P. Metabolomic biomarkers as strong correlates of Parkinson disease progression. Neurology. 2017;88(9):862-869.
114. Luan H, Liu LF, Tang Z, et al. Comprehensive urinary metabolomic profiling and identification of potential noninvasive marker for idiopathic Parkinson's disease. Scientific reports. 2015;5:13888.
115. Trezzi JP, Galozzi S, Jaeger C, et al. Distinct metabolomic signature in cerebrospinal fluid in early parkinson's disease. Movement disorders : official journal of the Movement Disorder Society. 2017;32(10):1401-1408.
116. Lewitt PA, Li J, Lu M, Beach TG, Adler CH, Guo L. 3-hydroxykynurenine and other Parkinson's disease biomarkers discovered by metabolomic analysis. Movement disorders : official journal of the Movement Disorder Society. 2013;28(12):1653-1660.
117. Trupp M, Jonsson P, Ohrfelt A, et al. Metabolite and peptide levels in plasma and CSF differentiating healthy controls from patients with newly diagnosed Parkinson's disease. Journal of Parkinson's disease. 2014;4(3):549-560.
118. Sinclair E, Trivedi DK, Sarkar D, et al. Metabolomics of sebum reveals lipid dysregulation in Parkinson's disease. Nature communications. 2021;12(1):1592.
119. Shao Y, Li T, Liu Z, et al. Comprehensive metabolic profiling of Parkinson's disease by liquid chromatography-mass spectrometry. Molecular neurodegeneration. 2021;16(1):4.
120. Hatano T, Saiki S, Okuzumi A, Mohney RP, Hattori N. Identification of novel biomarkers for Parkinson's disease by metabolomic technologies. Journal of neurology, neurosurgery, and psychiatry. 2016;87(3):295-301.
121. Kwon DH, Hwang JS, Kim SG, Jang YE, Shin TH, Lee G. Cerebrospinal Fluid Metabolome in Parkinson's Disease and Multiple System Atrophy. International journal of molecular sciences. 2022;23(3).
122. Saiki S, Sasazawa Y, Fujimaki M, et al. A metabolic profile of polyamines in parkinson disease: A promising biomarker. Annals of neurology. 2019;86(2):251-263.
123. LeWitt PA, Li J, Wu KH, Lu M. Diagnostic metabolomic profiling of Parkinson's disease biospecimens. Neurobiology of disease. 2023;177:105962.
124. Roede JR, Uppal K, Park Y, et al. Serum metabolomics of slow vs. rapid motor progression Parkinson's disease: a pilot study. PLoS One. 2013;8(10):e77629.
125. Solana-Manrique C, Sanz FJ, Torregrosa I, et al. Metabolic Alterations in a Drosophila Model of Parkinson's Disease Based on DJ-1 Deficiency. Cells. 2022;11(3).
126. Scholefield M, Church SJ, Taylor G, Knight D, Unwin RD, Cooper GJS. Multi-regional alterations in glucose and purine metabolic pathways in the Parkinson's disease dementia brain. NPJ Parkinson's disease. 2023;9(1):66.
127. Dunn L, Allen GF, Mamais A, et al. Dysregulation of glucose metabolism is an early event in sporadic Parkinson's disease. Neurobiology of aging. 2014;35(5):1111-1115.
128. Anandhan A, Jacome MS, Lei S, et al. Metabolic Dysfunction in Parkinson's Disease: Bioenergetics, Redox Homeostasis and Central Carbon Metabolism. Brain research bulletin. 2017;133:12-30.
129. Dorcely B, Katz K, Jagannathan R, et al. Novel biomarkers for prediabetes, diabetes, and associated complications. Diabetes, metabolic syndrome and obesity : targets and therapy. 2017;10:345-361.
130. Jin Q, Ma RCW. Metabolomics in Diabetes and Diabetic Complications: Insights from Epidemiological Studies. Cells. 2021;10(11).
131. Pallares-Méndez R, Aguilar-Salinas CA, Cruz-Bautista I, Del Bosque-Plata L. Metabolomics in diabetes, a review. Annals of medicine. 2016;48(1-2):89-102.
132. Fernstrom JD. Branched-chain amino acids and brain function. The Journal of nutrition. 2005;135(6 Suppl):1539s-1546s.
133. Breum L, Rasmussen MH, Hilsted J, Fernstrom JD. Twenty-four-hour plasma tryptophan concentrations and ratios are below normal in obese subjects and are not normalized by substantial weight reduction. The American journal of clinical nutrition. 2003;77(5):1112-1118.
134. Chen ZZ, Gerszten RE. Metabolomics and Proteomics in Type 2 Diabetes. Circulation research. 2020;126(11):1613-1627.
135. Adeva MM, Calviño J, Souto G, Donapetry C. Insulin resistance and the metabolism of branched-chain amino acids in humans. Amino acids. 2012;43(1):171-181.
136. Pauly RP, Maximova K, Coppens J, et al. Patient and technique survival among a Canadian multicenter nocturnal home hemodialysis cohort. Clinical journal of the American Society of Nephrology : CJASN. 2010;5(10):1815-1820.
137. Friedrich N. Metabolomics in diabetes research. The Journal of endocrinology. 2012;215(1):29-42.
138. Morze J, Wittenbecher C, Schwingshackl L, et al. Metabolomics and Type 2 Diabetes Risk: An Updated Systematic Review and Meta-analysis of Prospective Cohort Studies. Diabetes care. 2022;45(4):1013-1024.
139. Suhre K, Meisinger C, Döring A, et al. Metabolic footprint of diabetes: a multiplatform metabolomics study in an epidemiological setting. PLoS One. 2010;5(11):e13953.
140. Mooradian AD. Dyslipidemia in type 2 diabetes mellitus. Nature clinical practice Endocrinology & metabolism. 2009;5(3):150-159.
141. Adela R, Kasarla SS, Saquib N, et al. Untargeted metabolomics reveals altered branch chain amino acids, glucose and fat metabolism contributing to coronary artery disease among Indian diabetic patients. Molecular omics. 2023;19(4):321-329.
142. Tomar MS, Sharma A, Araniti F, Pateriya A, Shrivastava A, Tamrakar AK. Distinct Metabolomic Profiling of Serum Samples from High-Fat-Diet-Induced Insulin-Resistant Mice. ACS pharmacology & translational science. 2023;6(5):771-782.
2. Dar MA, Arafah A, Bhat KA, et al. Multiomics technologies: role in disease biomarker discoveries and therapeutics. Briefings in functional genomics. 2023;22(2):76-96.
3. Aderemi AV, Ayeleso AO, Oyedapo OO, Mukwevho E. Metabolomics: A Scoping Review of Its Role as a Tool for Disease Biomarker Discovery in Selected Non-Communicable Diseases. Metabolites. 2021;11(7).
4. Johnson CH, Ivanisevic J, Siuzdak G. Metabolomics: beyond biomarkers and towards mechanisms. Nature reviews Molecular cell biology. 2016;17(7):451-459.
5. Johnson CH, Patterson AD, Idle JR, Gonzalez FJ. Xenobiotic metabolomics: major impact on the metabolome. Annual review of pharmacology and toxicology. 2012;52:37-56.
6. Kim HM, Kang JS. Metabolomic Studies for the Evaluation of Toxicity Induced by Environmental Toxicants on Model Organisms. Metabolites. 2021;11(8).
7. Whitfield PD, German AJ, Noble PJ. Metabolomics: an emerging post-genomic tool for nutrition. The British journal of nutrition. 2004;92(4):549-555.
8. Bino RJ, Hall RD, Fiehn O, et al. Potential of metabolomics as a functional genomics tool. Trends in plant science. 2004;9(9):418-425.
9. Wishart DS. Emerging applications of metabolomics in drug discovery and precision medicine. Nature reviews Drug discovery. 2016;15(7):473-484.
10. Rinschen MM, Ivanisevic J, Giera M, Siuzdak G. Identification of bioactive metabolites using activity metabolomics. Nature reviews Molecular cell biology. 2019;20(6):353-367.
11. Liu X, Locasale JW. Metabolomics: A Primer. Trends in biochemical sciences. 2017;42(4):274-284.
12. Zamboni N, Saghatelian A, Patti GJ. Defining the metabolome: size, flux, and regulation. Molecular cell. 2015;58(4):699-706.
13. Gika HG, Zisi C, Theodoridis G, Wilson ID. Protocol for quality control in metabolic profiling of biological fluids by U(H)PLC-MS. Journal of chromatography B, Analytical technologies in the biomedical and life sciences. 2016;1008:15-25.
14. Ashrafian H, Sounderajah V, Glen R, et al. Metabolomics: The Stethoscope for the Twenty-First Century. Medical principles and practice : international journal of the Kuwait University, Health Science Centre. 2021;30(4):301-310.
15. Pang H, Jia W, Hu Z. Emerging Applications of Metabolomics in Clinical Pharmacology. Clinical pharmacology and therapeutics. 2019;106(3):544-556.
16. Gonzalez-Covarrubias V, Martínez-Martínez E, Del Bosque-Plata L. The Potential of Metabolomics in Biomedical Applications. Metabolites. 2022;12(2).
17. Beger RD. A review of applications of metabolomics in cancer. Metabolites. 2013;3(3):552-574.
18. Bourgognon JM, Steinert JR. The metabolome identity: basis for discovery of biomarkers in neurodegeneration. Neural regeneration research. 2019;14(3):387-390.
19. Wang JH, Byun J, Pennathur S. Analytical approaches to metabolomics and applications to systems biology. Seminars in nephrology. 2010;30(5):500-511.
20. Zhang XW, Li QH, Xu ZD, Dou JJ. Mass spectrometry-based metabolomics in health and medical science: a systematic review. RSC advances. 2020;10(6):3092-3104.
21. Dettmer K, Aronov PA, Hammock BD. Mass spectrometry-based metabolomics. Mass spectrometry reviews. 2007;26(1):51-78.
22. Fiehn O. Metabolomics by Gas Chromatography-Mass Spectrometry: Combined Targeted and Untargeted Profiling. Current protocols in molecular biology. 2016;114:30.34.31-30.34.32.
23. Kiseleva O, Kurbatov I, Ilgisonis E, Poverennaya E. Defining Blood Plasma and Serum Metabolome by GC-MS. Metabolites. 2021;12(1).
24. Mostafa A, Edwards M, Górecki T. Optimization aspects of comprehensive two-dimensional gas chromatography. Journal of chromatography A. 2012;1255:38-55.
25. Allen DR, McWhinney BC. Quadrupole Time-of-Flight Mass Spectrometry: A Paradigm Shift in Toxicology Screening Applications. The Clinical biochemist Reviews. 2019;40(3):135-146.
26. Zhou B, Xiao JF, Tuli L, Ressom HW. LC-MS-based metabolomics. Molecular bioSystems. 2012;8(2):470-481.
27. Singh RR, Chao A, Phillips KA, et al. Expanded coverage of non-targeted LC-HRMS using atmospheric pressure chemical ionization: a case study with ENTACT mixtures. Analytical and bioanalytical chemistry. 2020;412(20):4931-4939.
28. Xiao JF, Zhou B, Ressom HW. Metabolite identification and quantitation in LC-MS/MS-based metabolomics. Trends in analytical chemistry : TRAC. 2012;32:1-14.
29. Liu X, Tian X, Qinghong S, et al. Characterization of LC-MS based urine metabolomics in healthy children and adults. PeerJ. 2022;10:e13545.
30. Adamski J. Genome-wide association studies with metabolomics. Genome medicine. 2012;4(4):34.
31. Nagana Gowda GA, Raftery D. NMR-Based Metabolomics. Advances in experimental medicine and biology. 2021;1280:19-37.
32. Nerli S, McShan AC, Sgourakis NG. Chemical shift-based methods in NMR structure determination. Progress in nuclear magnetic resonance spectroscopy. 2018;106-107:1-25.
33. Belhaj MR, Lawler NG, Hoffman NJ. Metabolomics and Lipidomics: Expanding the Molecular Landscape of Exercise Biology. Metabolites. 2021;11(3).
34. Crook AA, Powers R. Quantitative NMR-Based Biomedical Metabolomics: Current Status and Applications. Molecules (Basel, Switzerland). 2020;25(21).
35. Gowda GA, Zhang S, Gu H, Asiago V, Shanaiah N, Raftery D. Metabolomics-based methods for early disease diagnostics. Expert review of molecular diagnostics. 2008;8(5):617-633.
36. Kumar D, Gupta A, Nath K. NMR-based metabolomics of prostate cancer: a protagonist in clinical diagnostics. Expert review of molecular diagnostics. 2016;16(6):651-661.
37. Xi B, Gu H, Baniasadi H, Raftery D. Statistical analysis and modeling of mass spectrometry-based metabolomics data. Methods in molecular biology (Clifton, NJ). 2014;1198:333-353.
38. Saccenti E, Hoefsloot HCJ, Smilde AK, Westerhuis JA, Hendriks MMWB. Reflections on univariate and multivariate analysis of metabolomics data. Metabolomics : Official journal of the Metabolomic Society. 2014;10(3):361-374.
39. Pang Z, Chong J, Zhou G, et al. MetaboAnalyst 5.0: narrowing the gap between raw spectra and functional insights. Nucleic acids research. 2021;49(W1):W388-w396.
40. Xia J, Psychogios N, Young N, Wishart DS. MetaboAnalyst: a web server for metabolomic data analysis and interpretation. Nucleic acids research. 2009;37(Web Server issue):W652-660.
41. Gowda GA, Djukovic D. Overview of mass spectrometry-based metabolomics: opportunities and challenges. Methods in molecular biology (Clifton, NJ). 2014;1198:3-12.
42. Costa C, Maraschin M, Rocha M. An R package for the integrated analysis of metabolomics and spectral data. Computer methods and programs in biomedicine. 2016;129:117-124.
43. Sumner LW, Amberg A, Barrett D, et al. Proposed minimum reporting standards for chemical analysis Chemical Analysis Working Group (CAWG) Metabolomics Standards Initiative (MSI). Metabolomics : Official journal of the Metabolomic Society. 2007;3(3):211-221.
44. Couch RD, Dailey A, Zaidi F, et al. Alcohol Induced Alterations to the Human Fecal VOC Metabolome. PLOS ONE. 2015;10(3):e0119362.
45. Mahmud I, Thapaliya M, Boroujerdi A, Chowdhury K. NMR-based metabolomics study of the biochemical relationship between sugarcane callus tissues and their respective nutrient culture media. Analytical and bioanalytical chemistry. 2014;406(24):5997-6005.
46. Kwak S. Are Only p-Values Less Than 0.05 Significant? A p-Value Greater Than 0.05 Is Also Significant! Journal of lipid and atherosclerosis. 2023;12(2):89-95.
47. Tzoulaki I, Ebbels TM, Valdes A, Elliott P, Ioannidis JP. Design and analysis of metabolomics studies in epidemiologic research: a primer on -omic technologies. American journal of epidemiology. 2014;180(2):129-139.
48. Worley B, Powers R. Multivariate Analysis in Metabolomics. Current Metabolomics. 2013;1(1):92-107.
49. Jolliffe IT, Cadima J. Principal component analysis: a review and recent developments. Philosophical transactions Series A, Mathematical, physical, and engineering sciences. 2016;374(2065):20150202.
50. Worley B, Powers R. PCA as a practical indicator of OPLS-DA model reliability. Current Metabolomics. 2016;4(2):97-103.
51. Debik J, Sangermani M, Wang F, Madssen TS, Giskeødegård GF. Multivariate analysis of NMR-based metabolomic data. NMR in biomedicine. 2022;35(2):e4638.
52. Moholdt T, Parr EB, Devlin BL, Debik J, Giskeødegård G, Hawley JA. The effect of morning vs evening exercise training on glycaemic control and serum metabolites in overweight/obese men: a randomised trial. Diabetologia. 2021;64(9):2061-2076.
53. Chang W-C. On Using Principal Components Before Separating a Mixture of Two Multivariate Normal Distributions. Journal of the Royal Statistical Society Series C (Applied Statistics). 1983;32(3):267-275.
54. Nyamundanda G, Brennan L, Gormley IC. Probabilistic principal component analysis for metabolomic data. BMC bioinformatics. 2010;11:571.
55. Gromski PS, Muhamadali H, Ellis DI, et al. A tutorial review: Metabolomics and partial least squares-discriminant analysis--a marriage of convenience or a shotgun wedding. Analytica chimica acta. 2015;879:10-23.
56. Worley B, Halouska S, Powers R. Utilities for quantifying separation in PCA/PLS-DA scores plots. Analytical biochemistry. 2013;433(2):102-104.
57. Lee LC, Liong CY, Jemain AA. Partial least squares-discriminant analysis (PLS-DA) for classification of high-dimensional (HD) data: a review of contemporary practice strategies and knowledge gaps. The Analyst. 2018;143(15):3526-3539.
58. Ruiz-Perez D, Guan H, Madhivanan P, Mathee K, Narasimhan G. So you think you can PLS-DA? BMC bioinformatics. 2020;21(Suppl 1):2.
59. Tan Y, Shi L, Tong W, Hwang GT, Wang C. Multi-class tumor classification by discriminant partial least squares using microarray gene expression data and assessment of classification models. Computational biology and chemistry. 2004;28(3):235-244.
60. Botella C, Ferré J, Boqué R. Classification from microarray data using probabilistic discriminant partial least squares with reject option. Talanta. 2009;80(1):321-328.
61. Ruiz-Perez D, Guan H, Madhivanan P, Mathee K, Narasimhan G. So you think you can PLS-DA? BMC bioinformatics. 2020;21(1):2.
62. KA LC, Boitard S, Besse P. Sparse PLS discriminant analysis: biologically relevant feature selection and graphical displays for multiclass problems. BMC bioinformatics. 2011;12:253.
63. Bastien P, Bertrand F, Meyer N, Maumy-Bertrand M. Deviance residuals-based sparse PLS and sparse kernel PLS regression for censored data. Bioinformatics (Oxford, England). 2015;31(3):397-404.
64. Chung D, Keles S. Sparse partial least squares classification for high dimensional data. Statistical applications in genetics and molecular biology. 2010;9(1):Article17.
65. Lee D, Lee Y, Pawitan Y, Lee W. Sparse partial least-squares regression for high-throughput survival data analysis. Statistics in medicine. 2013;32(30):5340-5352.
66. Vajargah KF, Sadeghi-Bazargani H, Mehdizadeh-Esfanjani R, Savadi-Oskouei D, Farhoudi M. OPLS statistical model versus linear regression to assess sonographic predictors of stroke prognosis. Neuropsychiatric disease and treatment. 2012;8:387-392.
67. Shah SH, Kraus WE, Newgard CB. Metabolomic profiling for the identification of novel biomarkers and mechanisms related to common cardiovascular diseases: form and function. Circulation. 2012;126(9):1110-1120.
68. Collino S, Martin FP, Rezzi S. Clinical metabolomics paves the way towards future healthcare strategies. British journal of clinical pharmacology. 2013;75(3):619-629.
69. Buergel T, Steinfeldt J, Ruyoga G, et al. Metabolomic profiles predict individual multidisease outcomes. Nature medicine. 2022;28(11):2309-2320.
70. Martínez-Reyes I, Chandel NS. Cancer metabolism: looking forward. Nature reviews Cancer. 2021;21(10):669-680.
71. Schmidt DR, Patel R, Kirsch DG, Lewis CA, Vander Heiden MG, Locasale JW. Metabolomics in cancer research and emerging applications in clinical oncology. CA: a cancer journal for clinicians. 2021;71(4):333-358.
72. Han J, Li Q, Chen Y, Yang Y. Recent Metabolomics Analysis in Tumor Metabolism Reprogramming. Frontiers in molecular biosciences. 2021;8:763902.
73. Nascentes Melo LM, Lesner NP, Sabatier M, Ubellacker JM, Tasdogan A. Emerging metabolomic tools to study cancer metastasis. Trends in cancer. 2022;8(12):988-1001.
74. An R, Yu H, Wang Y, et al. Integrative analysis of plasma metabolomics and proteomics reveals the metabolic landscape of breast cancer. Cancer & metabolism. 2022;10(1):13.
75. Hassan MA, Al-Sakkaf K, Shait Mohammed MR, et al. Integration of Transcriptome and Metabolome Provides Unique Insights to Pathways Associated With Obese Breast Cancer Patients. Frontiers in oncology. 2020;10:804.
76. Resurreccion EP, Fong KW. The Integration of Metabolomics with Other Omics: Insights into Understanding Prostate Cancer. Metabolites. 2022;12(6).
77. Liberti MV, Locasale JW. The Warburg Effect: How Does it Benefit Cancer Cells? Trends in biochemical sciences. 2016;41(3):211-218.
78. DeBerardinis RJ, Mancuso A, Daikhin E, et al. Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proceedings of the National Academy of Sciences of the United States of America. 2007;104(49):19345-19350.
79. Lafita-Navarro MC, Perez-Castro L, Zacharias LG, Barnes S, DeBerardinis RJ, Conacci-Sorrell M. The transcription factors aryl hydrocarbon receptor and MYC cooperate in the regulation of cellular metabolism. The Journal of biological chemistry. 2020;295(35):12398-12407.
80. Sica V, Bravo-San Pedro JM, Stoll G, Kroemer G. Oxidative phosphorylation as a potential therapeutic target for cancer therapy. International journal of cancer. 2020;146(1):10-17.
81. Ashton TM, McKenna WG, Kunz-Schughart LA, Higgins GS. Oxidative Phosphorylation as an Emerging Target in Cancer Therapy. Clinical cancer research : an official journal of the American Association for Cancer Research. 2018;24(11):2482-2490.
82. Giddings EL, Champagne DP, Wu MH, et al. Mitochondrial ATP fuels ABC transporter-mediated drug efflux in cancer chemoresistance. Nature communications. 2021;12(1):2804.
83. Caro P, Kishan AU, Norberg E, et al. Metabolic signatures uncover distinct targets in molecular subsets of diffuse large B cell lymphoma. Cancer cell. 2012;22(4):547-560.
84. Patra KC, Hay N. The pentose phosphate pathway and cancer. Trends in biochemical sciences. 2014;39(8):347-354.
85. Li L, Zheng X, Zhou Q, et al. Metabolomics-Based Discovery of Molecular Signatures for Triple Negative Breast Cancer in Asian Female Population. Scientific reports. 2020;10(1):370.
86. Lima AR, Pinto J, Bastos ML, Carvalho M, Guedes de Pinho P. NMR-based metabolomics studies of human prostate cancer tissue. Metabolomics : Official journal of the Metabolomic Society. 2018;14(7):88.
87. Yu L, Lai Q, Feng Q, Li Y, Feng J, Xu B. Serum Metabolic Profiling Analysis of Chronic Gastritis and Gastric Cancer by Untargeted Metabolomics. Frontiers in oncology. 2021;11:636917.
88. Tripathi P, Somashekar BS, Ponnusamy M, et al. HR-MAS NMR tissue metabolomic signatures cross-validated by mass spectrometry distinguish bladder cancer from benign disease. Journal of proteome research. 2013;12(7):3519-3528.
89. Zhou H, Li L, Zhao H, et al. A Large-Scale, Multi-Center Urine Biomarkers Identification of Coronary Heart Disease in TCM Syndrome Differentiation. Journal of proteome research. 2019;18(5):1994-2003.
90. Ullah E, El-Menyar A, Kunji K, et al. METABOLOMICS REVEALS PERTURBATIONS IN ARGININE-NO METABOLISM, PURINE BIOSYNTHESIS AND CELLULAR ENERGY CHARGE IN PATIENTS WITH CORONARY HEART DISEASE. Journal of the American College of Cardiology. 2021;77:22.
91. Kordalewska M, Markuszewski MJ. Metabolomics in cardiovascular diseases. Journal of pharmaceutical and biomedical analysis. 2015;113:121-136.
92. Senn T, Hazen SL, Tang WH. Translating metabolomics to cardiovascular biomarkers. Progress in cardiovascular diseases. 2012;55(1):70-76.
93. Li B, Gao G, Zhang W, et al. Metabolomics analysis reveals an effect of homocysteine on arachidonic acid and linoleic acid metabolism pathway. Molecular medicine reports. 2018;17(5):6261-6268.
94. Stratmann B, Richter K, Wang R, et al. Metabolomic Signature of Coronary Artery Disease in Type 2 Diabetes Mellitus. International journal of endocrinology. 2017;2017:7938216.
95. Rangel-Huerta OD, Pastor-Villaescusa B, Gil A. Are we close to defining a metabolomic signature of human obesity? A systematic review of metabolomics studies. Metabolomics : Official journal of the Metabolomic Society. 2019;15(6):93.
96. Taghizadeh H, Emamgholipour S, Hosseinkhani S, et al. The association between acylcarnitine and amino acids profile and metabolic syndrome and its components in Iranian adults: Data from STEPs 2016. Frontiers in endocrinology. 2023;14:1058952.
97. Gupta S, Sharma U. Metabolomics of neurological disorders in India. Analytical Science Advances. 2021;2(11-12):594-610.
98. Quintero ME, Pontes JGM, Tasic L. Metabolomics in degenerative brain diseases. Brain research. 2021;1773:147704.
99. Roche S, Gabelle A, Lehmann S. Clinical proteomics of the cerebrospinal fluid: Towards the discovery of new biomarkers. Proteomics Clinical applications. 2008;2(3):428-436.
100. Huo Z, Yu L, Yang J, Zhu Y, Bennett DA, Zhao J. Brain and blood metabolome for Alzheimer's dementia: findings from a targeted metabolomics analysis. Neurobiology of aging. 2020;86:123-133.
101. Haass C, Kaether C, Thinakaran G, Sisodia S. Trafficking and proteolytic processing of APP. Cold Spring Harbor perspectives in medicine. 2012;2(5):a006270.
102. Liu CC, Liu CC, Kanekiyo T, Xu H, Bu G. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nature reviews Neurology. 2013;9(2):106-118.
103. Burke SL, Maramaldi P, Cadet T, Kukull W. Associations between depression, sleep disturbance, and apolipoprotein E in the development of Alzheimer's disease: dementia. International psychogeriatrics. 2016;28(9):1409-1424.
104. Klosinski LP, Yao J, Yin F, et al. White Matter Lipids as a Ketogenic Fuel Supply in Aging Female Brain: Implications for Alzheimer's Disease. EBioMedicine. 2015;2(12):1888-1904.
105. Wilkins JM, Trushina E. Application of Metabolomics in Alzheimer's Disease. Frontiers in neurology. 2017;8:719.
106. Horgusluoglu E, Neff R, Song WM, et al. Integrative metabolomics-genomics approach reveals key metabolic pathways and regulators of Alzheimer's disease. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2022;18(6):1260-1278.
107. Liang Q, Liu H, Zhang T, Jiang Y, Xing H, Zhang A-h. Metabolomics-based screening of salivary biomarkers for early diagnosis of Alzheimer's disease. RSC advances. 2015;5(116):96074-96079.
108. Batra R, Arnold M, Wörheide MA, et al. The landscape of metabolic brain alterations in Alzheimer's disease. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2022.
109. Varma VR, Oommen AM, Varma S, et al. Brain and blood metabolite signatures of pathology and progression in Alzheimer disease: A targeted metabolomics study. PLoS medicine. 2018;15(1):e1002482.
110. Fiehn O. Metabolomics--the link between genotypes and phenotypes. Plant molecular biology. 2002;48(1-2):155-171.
111. Aarsland D, Batzu L, Halliday GM, et al. Parkinson disease-associated cognitive impairment. Nature reviews Disease primers. 2021;7(1):47.
112. Shao Y, Le W. Recent advances and perspectives of metabolomics-based investigations in Parkinson's disease. Molecular neurodegeneration. 2019;14(1):3.
113. LeWitt PA, Li J, Lu M, Guo L, Auinger P. Metabolomic biomarkers as strong correlates of Parkinson disease progression. Neurology. 2017;88(9):862-869.
114. Luan H, Liu LF, Tang Z, et al. Comprehensive urinary metabolomic profiling and identification of potential noninvasive marker for idiopathic Parkinson's disease. Scientific reports. 2015;5:13888.
115. Trezzi JP, Galozzi S, Jaeger C, et al. Distinct metabolomic signature in cerebrospinal fluid in early parkinson's disease. Movement disorders : official journal of the Movement Disorder Society. 2017;32(10):1401-1408.
116. Lewitt PA, Li J, Lu M, Beach TG, Adler CH, Guo L. 3-hydroxykynurenine and other Parkinson's disease biomarkers discovered by metabolomic analysis. Movement disorders : official journal of the Movement Disorder Society. 2013;28(12):1653-1660.
117. Trupp M, Jonsson P, Ohrfelt A, et al. Metabolite and peptide levels in plasma and CSF differentiating healthy controls from patients with newly diagnosed Parkinson's disease. Journal of Parkinson's disease. 2014;4(3):549-560.
118. Sinclair E, Trivedi DK, Sarkar D, et al. Metabolomics of sebum reveals lipid dysregulation in Parkinson's disease. Nature communications. 2021;12(1):1592.
119. Shao Y, Li T, Liu Z, et al. Comprehensive metabolic profiling of Parkinson's disease by liquid chromatography-mass spectrometry. Molecular neurodegeneration. 2021;16(1):4.
120. Hatano T, Saiki S, Okuzumi A, Mohney RP, Hattori N. Identification of novel biomarkers for Parkinson's disease by metabolomic technologies. Journal of neurology, neurosurgery, and psychiatry. 2016;87(3):295-301.
121. Kwon DH, Hwang JS, Kim SG, Jang YE, Shin TH, Lee G. Cerebrospinal Fluid Metabolome in Parkinson's Disease and Multiple System Atrophy. International journal of molecular sciences. 2022;23(3).
122. Saiki S, Sasazawa Y, Fujimaki M, et al. A metabolic profile of polyamines in parkinson disease: A promising biomarker. Annals of neurology. 2019;86(2):251-263.
123. LeWitt PA, Li J, Wu KH, Lu M. Diagnostic metabolomic profiling of Parkinson's disease biospecimens. Neurobiology of disease. 2023;177:105962.
124. Roede JR, Uppal K, Park Y, et al. Serum metabolomics of slow vs. rapid motor progression Parkinson's disease: a pilot study. PLoS One. 2013;8(10):e77629.
125. Solana-Manrique C, Sanz FJ, Torregrosa I, et al. Metabolic Alterations in a Drosophila Model of Parkinson's Disease Based on DJ-1 Deficiency. Cells. 2022;11(3).
126. Scholefield M, Church SJ, Taylor G, Knight D, Unwin RD, Cooper GJS. Multi-regional alterations in glucose and purine metabolic pathways in the Parkinson's disease dementia brain. NPJ Parkinson's disease. 2023;9(1):66.
127. Dunn L, Allen GF, Mamais A, et al. Dysregulation of glucose metabolism is an early event in sporadic Parkinson's disease. Neurobiology of aging. 2014;35(5):1111-1115.
128. Anandhan A, Jacome MS, Lei S, et al. Metabolic Dysfunction in Parkinson's Disease: Bioenergetics, Redox Homeostasis and Central Carbon Metabolism. Brain research bulletin. 2017;133:12-30.
129. Dorcely B, Katz K, Jagannathan R, et al. Novel biomarkers for prediabetes, diabetes, and associated complications. Diabetes, metabolic syndrome and obesity : targets and therapy. 2017;10:345-361.
130. Jin Q, Ma RCW. Metabolomics in Diabetes and Diabetic Complications: Insights from Epidemiological Studies. Cells. 2021;10(11).
131. Pallares-Méndez R, Aguilar-Salinas CA, Cruz-Bautista I, Del Bosque-Plata L. Metabolomics in diabetes, a review. Annals of medicine. 2016;48(1-2):89-102.
132. Fernstrom JD. Branched-chain amino acids and brain function. The Journal of nutrition. 2005;135(6 Suppl):1539s-1546s.
133. Breum L, Rasmussen MH, Hilsted J, Fernstrom JD. Twenty-four-hour plasma tryptophan concentrations and ratios are below normal in obese subjects and are not normalized by substantial weight reduction. The American journal of clinical nutrition. 2003;77(5):1112-1118.
134. Chen ZZ, Gerszten RE. Metabolomics and Proteomics in Type 2 Diabetes. Circulation research. 2020;126(11):1613-1627.
135. Adeva MM, Calviño J, Souto G, Donapetry C. Insulin resistance and the metabolism of branched-chain amino acids in humans. Amino acids. 2012;43(1):171-181.
136. Pauly RP, Maximova K, Coppens J, et al. Patient and technique survival among a Canadian multicenter nocturnal home hemodialysis cohort. Clinical journal of the American Society of Nephrology : CJASN. 2010;5(10):1815-1820.
137. Friedrich N. Metabolomics in diabetes research. The Journal of endocrinology. 2012;215(1):29-42.
138. Morze J, Wittenbecher C, Schwingshackl L, et al. Metabolomics and Type 2 Diabetes Risk: An Updated Systematic Review and Meta-analysis of Prospective Cohort Studies. Diabetes care. 2022;45(4):1013-1024.
139. Suhre K, Meisinger C, Döring A, et al. Metabolic footprint of diabetes: a multiplatform metabolomics study in an epidemiological setting. PLoS One. 2010;5(11):e13953.
140. Mooradian AD. Dyslipidemia in type 2 diabetes mellitus. Nature clinical practice Endocrinology & metabolism. 2009;5(3):150-159.
141. Adela R, Kasarla SS, Saquib N, et al. Untargeted metabolomics reveals altered branch chain amino acids, glucose and fat metabolism contributing to coronary artery disease among Indian diabetic patients. Molecular omics. 2023;19(4):321-329.
142. Tomar MS, Sharma A, Araniti F, Pateriya A, Shrivastava A, Tamrakar AK. Distinct Metabolomic Profiling of Serum Samples from High-Fat-Diet-Induced Insulin-Resistant Mice. ACS pharmacology & translational science. 2023;6(5):771-782.